Cocrystal Pharma Inc (COCP) Stock Price, Quote & News

Company Profile

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a cl...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 262 7123

Website: www.cocrystalpharma.com

Address:

19805 North Creek Parkway, Bothell, United States

momo2021 Jun. 26 at 3:54 PM

$CDTX $COCP cc-42344 cocrystal is by far the most advanced H5N1 bird flu pill and seasonal on the planet the virology results are 1000x more powerful than tamiflu in phase 2a don't believe me do your own research if you liked the move in CDTX this will destroy that the stock is going to launch like no other v soon check please

0 · Reply

momo2021 Jun. 26 at 3:37 PM

$COCP $CDTX wait is anyone doubting robert gave out $CYN 1 hour ago a free-be up over 100% for real parabolic cash?

0 · Reply

momo2021 Jun. 26 at 3:27 PM

$CYN just pulled out $190K in profits woo hoey let the rest ride $COCP $CDTX

1 · Reply

momo2021 Jun. 26 at 3:24 PM

$COCP $CDTX next momo $CYN real parabolic pass through $50

0 · Reply

momo2021 Jun. 26 at 3:13 PM

$COCP $CDTX it was a free-be $CYN up $20+ already while we wait for cocrystal boom boom enjoy it well over $30 now on the next halt woo hoooooy

1 · Reply

momo2021 Jun. 26 at 3:07 PM

$CDTX @birdflustocks if you want real virology results for an antiviral pill for all seasonal influenza and H5N1 bird flu all strains look at $COCP cc-42344 nothing comes close and its a pill that will be stockpiled https://www.cocrystalpharma.com/news/press-releases/detail/207/cocrystal-pharmas-investigational-drug-candidate

1 · Reply

momo2021 Jun. 26 at 2:58 PM

$CDTX $COCP you peeps should be thanking real with the real momo $CYN if you listened you would have already been up $10 in 30 minutes

0 · Reply

momo2021 Jun. 26 at 1:08 PM

$COCP barda proof just need one drug like $CDTX but cocrystsal has 2 drugs https://www.cocrystalpharma.com/news/press-releases/detail/208/cocrystal-pharmas-novel-norovirus-antiviral-to-be

1 · Reply

momo2021 Jun. 26 at 12:35 PM

$COCP $OPK the original con man @Resurrected_Magic biscayne boy stalker @The_Original_Magic 8k posts removed for fraud by ST in 2022

0 · Reply

Resurrected_Magic Jun. 26 at 3:39 AM

$COCP scam

0 · Reply

Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference

May 29, 2025, 8:00 AM EDT - 4 weeks ago

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

May 28, 2025, 8:00 AM EDT - 4 weeks ago

Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference

May 15, 2025, 8:00 AM EDT - 6 weeks ago

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Apr 24, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Apr 16, 2025, 8:00 AM EDT - 2 months ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 6, 2025, 8:00 AM EST - 4 months ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Dec 31, 2024, 2:21 PM EST - 6 months ago

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Dec 31, 2024, 8:00 AM EST - 6 months ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Aug 19, 2024, 4:05 PM EDT - 11 months ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Aug 15, 2024, 3:00 PM EDT - 11 months ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

May 13, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

May 1, 2024, 8:00 AM EDT - 1 year ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Mar 5, 2024, 8:30 AM EST - 1 year ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Dec 6, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Nov 29, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Nov 27, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Nov 9, 2023, 8:00 AM EST - 1 year ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Oct 31, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Apr 10, 2023, 8:30 AM EDT - 2 years ago

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Jan 26, 2023, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Participation in Virtual Investor Events

Jan 23, 2023, 9:00 AM EST - 2 years ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Dec 1, 2022, 4:05 PM EST - 2 years ago

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Nov 17, 2022, 8:00 AM EST - 2 years ago

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Nov 1, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Oct 26, 2022, 8:00 AM EDT - 2 years ago

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

Oct 5, 2022, 8:00 AM EDT - 2 years ago

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Oct 3, 2022, 4:05 PM EDT - 2 years ago

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Aug 8, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Aug 3, 2022, 9:00 AM EDT - 3 years ago

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

May 18, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 11, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Apr 19, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Apr 12, 2022, 11:08 AM EDT - 3 years ago

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

Apr 12, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Mar 23, 2022, 4:05 PM EDT - 3 years ago

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Mar 22, 2022, 8:00 AM EDT - 3 years ago

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Mar 10, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Jan 27, 2022, 12:22 PM EST - 3 years ago

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Jan 27, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Jan 6, 2022, 8:00 AM EST - 3 years ago

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Dec 22, 2021, 11:43 AM EST - 3 years ago

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Dec 22, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Dec 2, 2021, 8:00 AM EST - 3 years ago

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

Dec 1, 2021, 4:05 PM EST - 3 years ago

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

momo2021 Jun. 26 at 3:54 PM

0 · Reply

momo2021 Jun. 26 at 3:37 PM

$COCP $CDTX wait is anyone doubting robert gave out $CYN 1 hour ago a free-be up over 100% for real parabolic cash?

0 · Reply

momo2021 Jun. 26 at 3:27 PM

$CYN just pulled out $190K in profits woo hoey let the rest ride $COCP $CDTX

1 · Reply

momo2021 Jun. 26 at 3:24 PM

$COCP $CDTX next momo $CYN real parabolic pass through $50

0 · Reply

momo2021 Jun. 26 at 3:13 PM

$COCP $CDTX it was a free-be $CYN up $20+ already while we wait for cocrystal boom boom enjoy it well over $30 now on the next halt woo hoooooy

1 · Reply

momo2021 Jun. 26 at 3:07 PM

1 · Reply

momo2021 Jun. 26 at 2:58 PM

$CDTX $COCP you peeps should be thanking real with the real momo $CYN if you listened you would have already been up $10 in 30 minutes

0 · Reply

momo2021 Jun. 26 at 1:08 PM

$COCP barda proof just need one drug like $CDTX but cocrystsal has 2 drugs https://www.cocrystalpharma.com/news/press-releases/detail/208/cocrystal-pharmas-novel-norovirus-antiviral-to-be

1 · Reply

momo2021 Jun. 26 at 12:35 PM

$COCP $OPK the original con man @Resurrected_Magic biscayne boy stalker @The_Original_Magic 8k posts removed for fraud by ST in 2022

0 · Reply

Resurrected_Magic Jun. 26 at 3:39 AM

$COCP scam

0 · Reply

bulmar Jun. 24 at 6:13 PM

$COCP All indexes are soaring and CoCrystal has news but the stock tanks. 🗑️

1 · Reply

momo2021 Jun. 23 at 1:59 PM

$CDTX $COCP congrats to you great call and good comparison to cocrystal for major upside from here instead of getting 100% move I will get a 2000% move in cocrystal

1 · Reply

Seanhere Jun. 23 at 1:58 PM

$CDTX $COCP who is the crazy pumper girl? What’s her account name?

1 · Reply

momo2021 Jun. 23 at 1:54 PM

$CDTX impressive move the crazy pumper girl called it right so congrats to her it was a big one no doubts- except she now says $300 which any body knows this is a vaccine inject not a oral pill big diff so now you have a mkt cap $600 milly vs $COCP $15 milly in phase 2a on influenza oral that acutally blocks H5n1 which cidara 388 does not and will never get stock piled by us gov

2 · Reply

prismmarketview Jun. 20 at 1:08 PM

$COCP https://prismmarketview.com/cocrystal-pharma-advances-first-in-class-norovirus-antiviral-cdi-988-gains-visibility-ahead-of-human-challenge-trial/

1 · Reply

JarvisFlow Jun. 20 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Cocrystal Pharma ( $COCP ), setting the rating to Buy with a target price of 7 → 6.

0 · Reply

momo2021 Jun. 17 at 1:16 PM

$COCP big talker with no money meanwhile there are 13,000 shares short out of 10.2m you must be the outlier perhaps you should post a winner one time for more followers LOL

0 · Reply

momo2021 Jun. 17 at 1:13 PM

$COCP Poor bashers did you ever hear of non dilutive pharma partnership big money licence deal or gov funding thats what mgmt told investors not trash talkers whom never made a dime in the mkt hey just look at your ST accounts all losses if not prove it Sad LOL

0 · Reply

xDOUGx Jun. 17 at 12:01 PM

$COCP is likely to run out of money soon—within 2 to 3 months at most—leading to another stock dilution. This situation seems geared toward ensuring that their investors can keep paying their salaries. There have been no results or completed projects for years. It feels like investors are subsidizing their salaries while they remain inactive. We might eventually see this stock featured on a TV show highlighting how the owners defrauded investors for years.

1 · Reply

xDOUGx Jun. 17 at 11:57 AM

$COCP down down down

0 · Reply

bulmar Jun. 16 at 9:50 PM

$COCP fucking trash.

0 · Reply

bulmar Jun. 13 at 5:09 PM

$COCP Martin and Sam just collecting checks it appears.. Produce something please.

0 · Reply

Market Cap	15.76M
Revenue (ttm)	0.00
Net Income (ttm)	-17.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,600
Avg Vol	19,712
Day's Range	N/A - N/A
Shares Out	10.17M
Stochastic %K	39%
Beta	2.15
Analysts	Strong Sell
Price Target	$8.00